We are live on ! Find out more
SCM

Silverarc Capital Management Portfolio holdings

AUM $962M
1-Year Est. Return 524.64%
This Fund
S&P 500
This Quarter Est. Return
+37.22%
1 Year Est. Return
+524.64%
3 Year Est. Return
+2,765.44%
5 Year Est. Return
+10,523.08%
10 Year Est. Return
–
AUM
$296M
AUM Growth
-$29.1M
Cap. Flow
-$1.25M
Cap. Flow %
-0.42%
Top 10 Hldgs %
37.63%
Holding
99
New
29
Increased
28
Reduced
20
Closed
20

Top Buys

Rank Stock Value
1
PSTX
Poseida Therapeutics, Inc. Common Stock
PSTX
+$7.19M
2
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$6.21M
3
VRAY
ViewRay, Inc.
VRAY
+$5.34M
4
PLRX icon
Pliant Therapeutics
PLRX
+$4.01M
5
NKTX icon
Nkarta
NKTX
+$3.6M

Top Sells

Rank Stock Value
1
ITCI
Intra-Cellular Therapies Inc.
ITCI
+$9.29M
2
APLS
Apellis Pharmaceuticals
APLS
+$5.87M
3
SGEN
Seagen Inc. Common Stock
SGEN
+$4.91M
4
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$4.34M
5
BIIB icon
Biogen
BIIB
+$4.25M

Sector Composition

Rank Sector Weight
1 Healthcare 79.75%
2 Miscellaneous 20.25%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BLU
1
DELISTED
BELLUS Health Inc.
BLU
$17.5M 5.91%
1,655,775
+92,818
+6% +$986K
RLMD icon
2
PUT
Relmada Therapeutics
RLMD
$462M
$14.5M 4.92%
+393,000
New +$10.9M
RXDX
3
PUT
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
$12.1M 4.09%
204,700
-97,000
-32% -$4.44M
VCYT icon
4
Veracyte
VCYT
$3.48B
$11.1M 3.74%
665,854
-52,935
-7% -$1.19M
AKRO
5
DELISTED
Akero Therapeutics
AKRO
$10.2M 3.46%
300,000
+39,675
+15% +$607K
AVXL icon
6
PUT
Anavex Life Sciences
AVXL
$277M
$9.73M 3.29%
942,500
+25,400
+3% +$268K
MORF
7
DELISTED
Morphic Holding, Inc. Common Stock
MORF
$9.18M 3.11%
324,421
-94,239
-23% -$2.63M
COGT icon
8
Cogent Biosciences
COGT
$6.02B
$9.05M 3.06%
606,608
-214,346
-26% -$2.94M
PSTX
9
DELISTED
Poseida Therapeutics, Inc. Common Stock
PSTX
$9.02M 3.05%
2,554,277
+2,173,671
+571% +$7.19M
XENE icon
10
Xenon Pharmaceuticals
XENE
$5.81B
$8.88M 3%
245,992
+13,362
+6% +$480K
ACRS icon
11
Aclaris Therapeutics
ACRS
$885M
$8.56M 2.9%
543,776
+4,231
+0.8% +$66.7K
VRAY
12
DELISTED
ViewRay, Inc.
VRAY
$8.46M 2.86%
2,324,066
+1,591,326
+217% +$5.34M
ISEE
13
PUT
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$7.95M 2.69%
443,100
+12,200
+3% +$160K
MRSN
14
DELISTED
Mersana Therapeutics
MRSN
$6.72M 2.27%
39,763
+5,763
+17% +$937K
PRTA icon
15
Prothena Corp
PRTA
$479M
$6.67M 2.26%
+110,000
New +$3.48M
ALNY icon
16
Alnylam Pharmaceuticals
ALNY
$31.7B
$6.51M 2.2%
+32,545
New +$6.21M
VERU icon
17
PUT
Veru
VERU
$44.8M
$6.34M 2.14%
55,000
-23,040
-30% -$3.32M
ITCI
18
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$6.33M 2.14%
136,126
-177,836
-57% -$9.29M
APEN
19
DELISTED
Apollo Endosurgery, Inc.
APEN
$6.26M 2.12%
1,136,206
+61,327
+6% +$340K
MRUS
20
DELISTED
Merus
MRUS
$5.91M 2%
295,136
-173,977
-37% -$4.15M
CERS icon
21
Cerus
CERS
$534M
$5.82M 1.97%
1,616,459
-477,402
-23% -$2.28M
CTIC
22
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
$5.72M 1.94%
983,516
-396,595
-29% -$2.47M
CLNN icon
23
PUT
Clene
CLNN
$54.3M
$4.86M 1.64%
+86,740
New +$5.75M
INSM icon
24
Insmed
INSM
$25.9B
$4.83M 1.63%
224,016
+11,534
+5% +$277K
NKTX icon
25
Nkarta
NKTX
$198M
$4.77M 1.61%
362,377
+251,614
+227% +$3.6M
1
2 3 4

Similar funds

LGP
Leonard Green & Partners Los Angeles, California $962M AUM 35.11% 1-Year Est. Return
PL
Parthenon LLC Louisville, Kentucky $962M AUM 27.46% 1-Year Est. Return
LAM
L2 Asset Management Wayland, Massachusetts $963M AUM 38.06% 1-Year Est. Return
ACP
Aviance Capital Partners Naples, Florida $963M AUM 32.56% 1-Year Est. Return
GIG
Goodnow Investment Group Darien, Connecticut $964M AUM 2.51% 1-Year Est. Return
AAP
Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return
BEAM
Baker Ellis Asset Management Vancouver, Washington $964M AUM 39.24% 1-Year Est. Return
RAM
Ramirez Asset Management New York $960M AUM 30.25% 1-Year Est. Return

Silverarc Capital Management's Q3 2022 Portfolio in Review

As of Q3 2022, Silverarc Capital Management held 99 positions worth $296M, down 9% from $325M the previous quarter. Its ten largest holdings account for 38% of the portfolio.

Silverarc Capital Management's Q3 2022 filing shows 29 new, 28 increased, 20 reduced and 20 closed positions. Its largest new stake was Alnylam Pharmaceuticals: 32,545 shares worth $6.51M. The largest sale was Intra-Cellular Therapies Inc., an estimated $9.29M.

By sector, the portfolio is most concentrated in Healthcare at 80% of assets, up from 66% a quarter earlier, followed by Miscellaneous.

  • Silverarc Capital Management's largest Q3 2022 buy was Alnylam Pharmaceuticals: 32,545 shares worth $6.51M.
  • Silverarc Capital Management added most to Poseida Therapeutics, Inc. Common Stock in Q3 2022, an estimated $7.19M increase.
  • Silverarc Capital Management's biggest Q3 2022 reduction was Intra-Cellular Therapies Inc., cutting an estimated $9.29M.
  • Silverarc Capital Management fully exited Apellis Pharmaceuticals in Q3 2022, selling an estimated $5.87M.
  • Silverarc Capital Management's ten largest holdings make up 38% of its $296M portfolio in Q3 2022.
  • Silverarc Capital Management opened 29 new positions and closed 20 in Q3 2022.
  • Silverarc Capital Management's portfolio value fell 9% quarter-over-quarter to $296M.

Based on Silverarc Capital Management's 13F filing for Q3 2022, filed 28 Oct 2022.